Lymecycline: Difference between revisions
m Protected "Lymecycline": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
| Line 19: | Line 19: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
'''Lymecycline''' is a [[tetracycline antibiotics|tetracycline]] [[broad-spectrum antibiotic]] marketed by the pharmeceutical company Galderma[http://www.galderma.com]. It is approximately 5000 times more [[soluble]] than [[tetracycline]] base and is unique amongst tetracyclines in that it is [[Absorption (chemistry)|absorbed]] by the "active transport" process across the intestinal wall, making use of the same fast and efficient mechanism by which [[carbohydrate]]s are absorbed.{{ref|NZdrugdata}} | '''Lymecycline''' is a [[tetracycline antibiotics|tetracycline]] [[broad-spectrum antibiotic]] marketed by the pharmeceutical company Galderma[http://www.galderma.com]. It is approximately 5000 times more [[soluble]] than [[tetracycline]] base and is unique amongst tetracyclines in that it is [[Absorption (chemistry)|absorbed]] by the "active transport" process across the intestinal wall, making use of the same fast and efficient mechanism by which [[carbohydrate]]s are absorbed.{{ref|NZdrugdata}} | ||
| Line 51: | Line 51: | ||
[[Category:Tetracycline antibiotics]] | [[Category:Tetracycline antibiotics]] | ||
[[es:Limeciclina]] | [[es:Limeciclina]] | ||
Latest revision as of 17:03, 9 August 2012
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 100% (oral) |
| Metabolism | ? |
| Elimination half-life | ? |
| Excretion | renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | CH23N2O8 |
| Molar mass | 478.879 |
|
WikiDoc Resources for Lymecycline |
|
Articles |
|---|
|
Most recent articles on Lymecycline Most cited articles on Lymecycline |
|
Media |
|
Powerpoint slides on Lymecycline |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Lymecycline at Clinical Trials.gov Clinical Trials on Lymecycline at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Lymecycline
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Lymecycline Discussion groups on Lymecycline Patient Handouts on Lymecycline Directions to Hospitals Treating Lymecycline Risk calculators and risk factors for Lymecycline
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Lymecycline |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Lymecycline is a tetracycline broad-spectrum antibiotic marketed by the pharmeceutical company Galderma[1]. It is approximately 5000 times more soluble than tetracycline base and is unique amongst tetracyclines in that it is absorbed by the "active transport" process across the intestinal wall, making use of the same fast and efficient mechanism by which carbohydrates are absorbed.[2]
The greater absorption of Lymecycline allows for lower dosages to be used; the standard dose of 408 mg is equivalent to 300 mg tetracycline base, and in its action to 500 mg tetracycline hydrochloride. Lymecycline, unlike tetracycline hydrochloride, is soluble at all physiological pH values.
History
Lymecycline was released onto the pharmaceutical market in 1963.
Indications
Lymecycline, like other Tetracyclines, is used to treat a range of infections (see Tetracycline antibiotics group). Its better absorption profile makes it preferable to tetracycline for moderately severe acne and typically prescribed for 8 weeks at a time, but alternatives should be sought if no improvement occurs by 3 months.[3]
Dosage
The standard dose is 408mg (one capsule) twelve hourly by mouth. In particularly severe infections this dose may be increased to 1.224-1.632mg (three or four capsules) daily.
The 408mg once daily dosage for acne aids good drug compliance.
Formulation
Capsules containing 408mg of Lymecycline (brand name Tetrlysal 300).
References
- ^ New Zealand Datasheet August 2003
- ^ British National Formulary 45 March 2003
See also
- Pages using duplicate arguments in template calls
- Pages with script errors
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Tetracycline antibiotics